Talk to the Institute
Published mark

ANI PHARMACEUTICALS INC

NASDAQ: ANIP. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:052cb253-9284-4ca6-bffd-44cf6884846e
SEC CIK
0001023024
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 17, 2026
Newest evidence
May 3, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Nikhil LalwaniSince Apr 9, 2026
Chair
Not published
Independent
5 / 77 directors published
Published claims
263 distinct sources
Evidence records
130 pinned
Source conflicts
0None open

Built from 3 distinct sources and 13 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

EXECUTIVE APPOINTED

Chad Gassert executive of ANI PHARMACEUTICALS INC, effective 2026-04-09.

EffectiveEffective Apr 9, 2026E3

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Senior Vice President, Corporate Development StrategyChad GassertApr 2026currentSource reportedE3
Senior Vice President and Chief Human Resources OfficerKim DavisApr 2026currentSource reportedE5
Senior Vice President, General Counsel and Corporate SecretaryMeredith W. CookApr 2026currentSource reportedE7
Head of Research Development and Chief Operating Officer of New Jersey OperationsMuthusamy ShanmugamApr 2026currentSource reportedE8
President and Chief Executive OfficerNikhil LalwaniApr 2026currentSource reportedE9
Senior Vice President, GenericsOri GutwergApr 2026currentSource reportedE10
Senior Vice President, Finance and Chief Financial OfficerStephen P. CareyApr 2026currentSource reportedE11
Senior Vice President, Head of Established BrandsThomas RowlandApr 2026currentSource reportedE12
Senior Vice President, Head of Rare DiseaseChristopher MutzNot capturedunknownSource reportedE4
Senior Vice President and Chief Human Resources OfficerKrista DavisNot capturedunknownSource reportedE6

Board of directors

Evidence

7 directors published. 5 of 7 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
Antonio R. PeraIndependent2020Compensation, chairCompensation · ChairSource reportedE2
Jeanne A. ThomaIndependent2020CompensationSource reportedE2
Matthew J. Leonard, R.Ph.Independent2023None publishedSource reportedE2
Muthusamy ShanmugamNot independent2021None publishedSource reportedE2
Nikhil LalwaniNot independent2020None publishedSource reportedE2
Renee P. Tannenbaum, Pharm.D.Independent2022None publishedSource reportedE2
Thomas J. HaugheyIndependent2018Nominating and GovernanceSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
CompensationAntonio R. PeraAntonio R. Pera, Jeanne A. ThomaNot described in the published record
Compensation · ChairNot publishedAntonio R. PeraNot described in the published record
Nominating and GovernanceNot publishedThomas J. HaugheyNot described in the published record
Committee RecordCompensation: Chair Antonio R. Pera; Members Antonio R. Pera (Chair); Jeanne A. Thoma
Source reportedE13
company:052cb253-9284-4ca6-bffd-44cf6884846e:committee_record:22
Committee AppointmentAntonio R. Pera: chair, Compensation
Source reportedE13
company:052cb253-9284-4ca6-bffd-44cf6884846e:committee_appointment:23
Committee AppointmentJeanne A. Thoma: member, Compensation
Source reportedE13
company:052cb253-9284-4ca6-bffd-44cf6884846e:committee_appointment:24
Committee RecordNominating and Governance: Chair not stated; Members Thomas J. Haughey
Source reportedE13
company:052cb253-9284-4ca6-bffd-44cf6884846e:committee_record:25
Committee AppointmentThomas J. Haughey: member, Nominating and Governance
Source reportedE13
company:052cb253-9284-4ca6-bffd-44cf6884846e:committee_appointment:26

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerNikhil Lalwani, President and Chief Executive Officer, from Apr 9, 2026
Source reportedE9
company:052cb253-9284-4ca6-bffd-44cf6884846e:leadership_role:18
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingANIP (NASDAQ)
Source reportedE1
company:052cb253-9284-4ca6-bffd-44cf6884846e:security_listing:27
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameANI PHARMACEUTICALS INC
Source reportedE1
company:052cb253-9284-4ca6-bffd-44cf6884846e:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:052cb253-9284-4ca6-bffd-44cf6884846e:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
13 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 17, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    ANI PHARMACEUTICALS INC DEF 14A 2026-04-09
    sec proxy. Published Apr 9, 2026. Retrieved Apr 24, 2026. Cited by 7 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    ANIP DEF 14A executive officers
    sec filing. Published Apr 9, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    ANIP executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    ANIP DEF 14A executive officers
    sec filing. Published Apr 9, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    ANIP executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    ANIP DEF 14A executive officers
    sec filing. Published Apr 9, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  8. E8
    ANIP DEF 14A executive officers
    sec filing. Published Apr 9, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  9. E9
    ANIP DEF 14A executive officers
    sec filing. Published Apr 9, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  10. E10
    ANIP DEF 14A executive officers
    sec filing. Published Apr 9, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  11. E11
    ANIP DEF 14A executive officers
    sec filing. Published Apr 9, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  12. E12
    ANIP DEF 14A executive officers
    sec filing. Published Apr 9, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  13. E13
    Compensation
    board_seats. board seats. Cited by 5 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 17, 2026
  • Chad Gassert executive of ANI PHARMACEUTICALS INC, effective 2026-04-09.
  • Kim Davis executive of ANI PHARMACEUTICALS INC, effective 2026-04-09.
  • Meredith W. Cook executive of ANI PHARMACEUTICALS INC, effective 2026-04-09.
  • Muthusamy Shanmugam executive of ANI PHARMACEUTICALS INC, effective 2026-04-09.
  • Nikhil Lalwani executive of ANI PHARMACEUTICALS INC, effective 2026-04-09.
  • Ori Gutwerg executive of ANI PHARMACEUTICALS INC, effective 2026-04-09.
  • Stephen P. Carey executive of ANI PHARMACEUTICALS INC, effective 2026-04-09.
  • Thomas Rowland executive of ANI PHARMACEUTICALS INC, effective 2026-04-09.
  • Matthew J. Leonard, R.Ph. seat on ANI PHARMACEUTICALS INC, effective 2023-01-01.
  • Renee P. Tannenbaum, Pharm.D. seat on ANI PHARMACEUTICALS INC, effective 2022-01-01.
  • Muthusamy Shanmugam seat on ANI PHARMACEUTICALS INC, effective 2021-01-01.
  • Antonio R. Pera seat on ANI PHARMACEUTICALS INC, effective 2020-01-01.
  • Jeanne A. Thoma seat on ANI PHARMACEUTICALS INC, effective 2020-01-01.
  • Nikhil Lalwani seat on ANI PHARMACEUTICALS INC, effective 2020-01-01.
  • Jeanne A. Thoma member of Compensation, effective 2020-01-01.
  • Compensation · Chair committee of ANI PHARMACEUTICALS INC, effective 2020-01-01.
  • Antonio R. Pera member of Compensation · Chair, effective 2020-01-01.
  • Thomas J. Haughey seat on ANI PHARMACEUTICALS INC, effective 2018-01-01.
  • Thomas J. Haughey member of Nominating and Governance, effective 2018-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:052cb253-9284-4ca6-bffd-44cf6884846e, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/ani-pharmaceuticals-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership10
  4. Board7
  5. Committees3
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people17
  17. Subject and corrections6
  18. Evidence13
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:052cb253-9284-4ca6-bffd-44cf6884846e
  • Cite this recordANI PHARMACEUTICALS INC
  • Copy canonical URLregistry.alpha.ac/companies/ani-pharmaceuticals-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    ANI PHARMACEUTICALS INCCompany
  • Chad GassertPerson
  • Kim DavisPerson
  • Meredith W. CookPerson
  • Muthusamy ShanmugamPerson
  • Nikhil LalwaniPerson
  • Ori GutwergPerson
  • Stephen P. CareyPerson
  • Thomas RowlandPerson
  • Christopher MutzPerson
  • Krista DavisPerson
  • Antonio R. PeraPerson
  • Jeanne A. ThomaPerson
  • Matthew J. Leonard, R.Ph.Person
  • Muthusamy ShanmugamPerson
  • Nikhil LalwaniPerson
  • Renee P. Tannenbaum, Pharm.D.Person
  • Thomas J. HaugheyPerson
  • Sections
    OverviewANI PHARMACEUTICALS INC
  • MonitoringANI PHARMACEUTICALS INC
  • LeadershipANI PHARMACEUTICALS INC
  • BoardANI PHARMACEUTICALS INC
  • CommitteesANI PHARMACEUTICALS INC
  • Control and votingANI PHARMACEUTICALS INC
  • Authority to actANI PHARMACEUTICALS INC
  • FinancialsANI PHARMACEUTICALS INC
  • GovernanceANI PHARMACEUTICALS INC
  • RiskANI PHARMACEUTICALS INC
  • AI oversightANI PHARMACEUTICALS INC
  • LegalANI PHARMACEUTICALS INC
  • CompensationANI PHARMACEUTICALS INC
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.